on PHAXIAM THERAPEUTICS (isin : FR001400K4B1)
Suspension of the Listing of PHAXIAM Therapeutics
On March 6, 2025, PHAXIAM Therapeutics requested the suspension of trading of its shares on the Euronext Paris market. The company, listed under the ticker PHXM, is waiting to publish a subsequent press release to inform its investors. This decision comes as PHAXIAM continues to develop innovative treatments against resistant bacterial infections, using phages, natural viruses targeting critical bacteria. The three bacteria targeted by PHAXIAM are responsible for many hospital infections. The company remains a major player on various stock indices, in particular those dedicated to health and biotechnologies. The exact reasons for the suspension remain to be specified by PHAXIAM.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PHAXIAM THERAPEUTICS news